Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Her2 Negative Breast Cancer Patients
Interventions: DRUG: MM-121|DRUG: Placebo|DRUG: Exemestane
Sponsor: Merrimack Pharmaceuticals